Poolbeg Pharma, a clinical-stage biopharmaceutical company, has made a significant breakthrough in its AI-driven influenza program in collaboration with CytoReason. By combining Poolbeg’s disease progression data from influenza human challenge trials with CytoReason’s curated disease data and AI platform, multiple novel drug targets for the treatment of influenza have been identified. This discovery was made in just 15 months, thanks to the utilization of CytoReason’s cutting-edge AI technology. Additionally, the analysis independently confirmed the significance of the p38 MAP kinase pathway in influenza, providing further validation for Poolbeg’s POLB 001 program. The company is now actively exploring the best approach to develop these novel drug targets and create value. Poolbeg has previously had success with its AI program, having identified potential new drug candidates for Respiratory Syncytial Virus (RSV) in December 2022. Shareholders can expect further updates on the progress of this influenza program in the future.

To know more: About the original article click here.